Expression of Glioma-associated oncogene homolog 1 as biomarker with sonidegib in advanced basal cell carcinoma

The pivotal BOLT (Basal cell carcinoma Outcomes with LDE225 [sonidegib] Treatment) study established the durable efficacy and manageable toxicity of sonidegib 200 mg once daily (QD) through 42 months in patients with advanced basal cell carcinoma (BCC). This secondary analysis used expression of Gli...

Descripción completa

Detalles Bibliográficos
Autores principales: Dummer, Reinhard, Liu, Li, Squittieri, Nicholas, Gutzmer, Ralf, Lear, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500103/
https://www.ncbi.nlm.nih.gov/pubmed/32973971
http://dx.doi.org/10.18632/oncotarget.27735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500103/
https://www.ncbi.nlm.nih.gov/pubmed/32973971
http://dx.doi.org/10.18632/oncotarget.27735

Ejemplares similares